Please select the option that best describes you:
How would you approach adjuvant systemic therapy in a HR+ premenopausal patient over the age of 50?
Would you recommend using chemotherapy based on RxPonder regardless of Oncotype score in a premenopausal patient? Or would you hold chemotherapy since the SI showed no clear benefit for patients over 50?
Answer from: Medical Oncologist at Community Practice
Since you are citing the RxPONDER study, I assume this is a premenopausal woman over age 50 with N1 node positive disease.In the RxPONDER study, for premenopausal women, the 5-year HR for iDFS with chemo was 0.6. Same for distant DFS. But the benefit was mainly seen in premenopausal women under 50. ...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
This question gets to the heart of a conundrum. I will give some thoughts, but I know there are lots of opinions and I am curious what others think.The average age of menopause in the United States is 49.9 years old (Appiah et al., PMID 33821908). As a caveat, I do personally believe that breast can...